16,000 Shares in Bristol Myers Squibb Company $BMY Acquired by Alpine Woods Capital Investors LLC

Key Points

• Alpine Woods Capital Investors acquired 16,000 Bristol Myers Squibb shares valued at approximately $922,000, while institutional investors collectively own 76.41% of the company.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, on revenue of $12.97 billion, up 5.7% year over year.
• The company pays a quarterly dividend of $0.63 per share, equivalent to a 3.8% annualized yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $66.06.

Alpine Woods Capital Investors LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,000 shares of the biopharmaceutical company's stock, valued at approximately $922,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth $1,947,272,000. AQR Capital Management LLC increased its stake in Bristol Myers Squibb by 172.6% during the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock valued at $1,391,485,000 after purchasing an additional 16,332,924 shares in the last quarter. BlackRock Inc. raised its holdings in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Bristol Myers Squibb by 47.0% during the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock worth $1,321,308,000 after buying an additional 7,837,485 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Up 2.2%

BMY opened at $66.07 on Wednesday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10. The company's 50-day moving average is $59.94 and its 200 day moving average is $59.14. The firm has a market capitalization of $134.97 billion, a P/E ratio of 14.55, a PEG ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb's quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BMY shares. Cantor Fitzgerald reissued a "neutral" rating and set a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Citigroup reaffirmed a "neutral" rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. JPMorgan Chase & Co. lifted their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. Finally, Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 27th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source